PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Fluticasone propionate (Nasal) - Allergic rhinitis

PAD Profile : Fluticasone propionate (Nasal) - Allergic rhinitis

Keywords :
Hay fever, hayfever, nasal sprays, allergy, seasonal allergic rhinitis, pollen allergy, intranasal corticosteroids, INCS
Brand Names Include :
Flixonase, Nasofan

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Nasal spray
Important Information :
Beclometasone is the preferred intranasal steroid for allergic rhinitis. If fluticasone is required, prescribe as fluticasone furoate in Primary Care (less costly option). Prices may vary in secondary care. NOTE: ASPH recommend fluticasone furoate in paediatrics due to smaller nozzle size.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
01 January 2024

Committee Recommendations

Date
Committee Name
Narrative
05 April 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Fluticasone is considered to be a 3rd line agent for nasal allergic rhinitis - see local guidelines below. 

If fluticasone is necessary, prescribe as Avamys (fluticasone furoate 27.5mcg/dose).

Avamys is approxiamtely 40% less expensive than generic scripts for fluticasone propionate or branded Flixonase.

Associated BNF Codes

12. Ear, Nose and Oropharynx
12.02.01. Drugs used in nasal allergy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More